Artificial Intelligence to Personalize Prostate Cancer Treatment (the HypoElect Trial)
Status:
RECRUITING
Trial end date:
2027-08-31
Target enrollment:
Participant gender:
Summary
A prospective, single-arm phase II study is the individualization of RT for patients with high-risk localized PCa based on multimodal artificial intelligence (MMAI). All patients will receive the current standard of care: (i) a dose escalation to the prostate via HDR brachytherapy, (ii) two years of ADT and (iii) whole-pelvis UHF-RT (5 fractions).